Risankizumab

• Germany
• Healthcare
• Pharma & Biotech
• Science

Boehringer Ingelheim: Risankizumab (formerly BI 655066) shown to be more effective than placebo in patients with moderately-to-severely active Crohn’s disease

After 12 weeks, approximately twice as many patients with moderate-to-severe Crohn’s disease, the majority of whom had previously failed treatment…